FDA-approved Digestive & weight

Teduglutide

Also written as Gattex

Teduglutide is a GLP-2 analog. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as Gattex.

Regulatory status

Teduglutide has an FDA-approved product on the U.S. market, marketed as Gattex under application NDA203441.

The current label is held by Takeda Pharmaceuticals America, Inc.

From the FDA label

What Teduglutide is approved to treat

® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Teduglutide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on digestive & weight

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Teduglutide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides